title: Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
abstract: BACKGROUND
  The prognosis of patients with stage IV cutaneous T-cell lymphoma (CTCL) is grim and therapeutic options are limited. Treatment of advanced-stage CTCL is aimed at suppressing the dominant T-cell clone, which is typically present in the skin, peripheral blood, and lymph nodes.
  
  
  METHODS
  We detected the expansion of 1 T-cell clone expressing the T-cell receptor V beta 14 in the peripheral blood of a patient with stage IVA CTCL. Before initiation of combination therapy with photopheresis and low-dose interferon alpha, the dominant T-cell clone represented 84% of the total T-cell population. After successful therapy, this clone showed a dramatic decrease to 6% of the T-cell population after 6 months of treatment. This reduction in the percentage of the malignant T-cell population in response to therapy was paralleled by clinical skin improvement from initial generalized erythroderma to undetectable skin disease.
  
  
  CONCLUSIONS
  This case demonstrates that response to combination treatment with photopheresis and low-dose interferon alpha in patients with advanced CTCL may be accurately and quantitatively followed up by monitoring the percentage of the malignant T-cell clone (when identifiable) within the total circulating T-cell population by flow cytometry.
authors.affiliation: Harvard Skin Disease Research Center, Boston, MA 02115, USA.
authors.forename: Katalin
authors.initials: K
authors.lastname: Ferenczi
authors.forename: Nikhil
authors.initials: N
authors.lastname: Yawalkar
authors.forename: David
authors.initials: D
authors.lastname: Jones
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Kupper
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016516:CD4-CD8 Ratio; D002999:Clone Cells; D003131:Combined Modality Therapy; D005260:Female; D005434:Flow Cytometry; D015333:Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D018655:Lymphocyte Count; D016410:Lymphoma, T-Cell, Cutaneous / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D017893:Photopheresis; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha